|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| OPERATING ACTIVITIES | |||||
| Net loss | |||||
| Non-cash items: | |||||
| Depreciation and amortization | |||||
| Gain on sale of property and equipment | |||||
| Stock-based compensation expense | |||||
| Change in fair value of contingent consideration | |||||
| Non-cash royalty revenue | |||||
| Non-cash interest expense | |||||
| Restructuring, Settlement and Impairment Provisions | |||||
| Net accretion of investments in marketable securities | |||||
| Net change in operating items: | |||||
| Accounts receivable | |||||
| Prepaid expenses and other assets | |||||
| Accounts payable and accrued liabilities | |||||
| Change in deferred license revenue | |||||
| Other liabilities | |||||
| Net cash used in operating activities | |||||
| INVESTING ACTIVITIES | |||||
| Purchase of investments in marketable securities | |||||
| Disposition of investments in marketable securities | |||||
| Proceeds from sale of property and equipment | |||||
| Acquisition of property and equipment | |||||
| Net cash provided by investing activities | |||||
| FINANCING ACTIVITIES | |||||
| Issuance of common shares pursuant to Share Purchase Agreement | |||||
| Issuance of common shares pursuant to the Open Market Sale Agreement | |||||
| Issuance of common shares pursuant to exercise of stock options | |||||
| Issuance of common shares pursuant to ESPP | |||||
| Net cash provided by financing activities | |||||
| Effect of foreign exchange rate changes on cash and cash equivalents | |||||
| (Decrease) / increase in cash and cash equivalents | |||||
| Cash and cash equivalents, beginning of period | |||||
| Cash and cash equivalents, end of period | |||||
Loading...